Hence, to investigate the prognostic value of p53 in ESCC, we conducted a systematic review and meta‐analysis of all publicly available data with subgroup analysis of studies assessed as low risk of bias, and studies using immunohistochemistry (IHC) to determine p53 expression status or sequencing determine TP53 mutation status. This evidence concerns the gene TP53 and esophageal squamous cell carcinoma.